Twenty-seven primary sources, sortable and searchable

About the bibliography

The references on this page are the primary sources cited by the /index, /research, /dosage and /faq pages. They are listed below in citation-number order and rendered as a sortable, searchable table.

The sources fall into four groups. Biochemistry and mechanism papers from 1992 through 2011 establish the actin-binding, NF-κB and PINCH-ILK-Akt frameworks ^{[1][2][6][11]}. Preclinical efficacy papers from 1999 through 2025 cover dermal and corneal wound healing, cardiac repair, stroke, skeletal muscle and hair follicle, plus the recent hydrogel-delivery and hepatic-stellate-cell work ^{[3][4][5][7][8][9][10][12][18][20][21]}. Human clinical trial reports and registry entries cover the Phase I safety studies, the Phase III ophthalmic program, and the halted Phase II cardiac program ^{[13][14][15][16][17]}. The Esposito 2012 equine doping-control paper provides the only published PK data specific to the seven-residue fragment ^[22]. Two review papers organize the field ^[24][25]. The FDA Interim 503A Bulks List guidance and the 2024 PCAC briefing material define the current regulatory record ^[26][27].

All twenty-seven sources have a DOI or a registry identifier and link to the publisher, PubMed, PMC, or ClinicalTrials.gov.

The full list

The table is sortable by citation number, year, first author and journal, and searchable across the citation text. The default sort is by citation number.